NCT04763408 (STELLAR) is a clinical trial of Lenvatinib in Carcinoma, Hepatocellular, sponsored by Eisai Inc..

Who is sponsoring NCT04763408?

NCT04763408 is sponsored by Eisai Inc..

What drugs are being tested in NCT04763408?

Interventions in NCT04763408: Lenvatinib, Sorafenib.

What condition does NCT04763408 study?

NCT04763408 studies Carcinoma, Hepatocellular.

Is NCT04763408 still recruiting?

NCT04763408 is currently completed. Last updated 18 July 2024.

Last reviewed 2024-07-18 · How we verify

NCT04763408: STELLAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma

Completed Last updated 18 July 2024

What this trial tests

trial testing Lenvatinib in Carcinoma, Hepatocellular in 335 participants. Completed in 13 December 2023.

Timeline

9 April 2021

Primary endpoint
13 December 2023

13 December 2023

Quick facts

Lead sponsor	Eisai Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	335
Start date	9 April 2021
Primary completion	13 December 2023
Estimated completion	13 December 2023
Sites	44 locations across Italy, Russia, Austria, Sweden, United Kingdom, Germany, Australia, Portugal

Drugs / interventions tested

Lenvatinib (LENVATINIB) — full drug profile →
Sorafenib (SORAFENIB) — full drug profile →

Conditions studied

Carcinoma, Hepatocellular — all drugs for Carcinoma, Hepatocellular →

Sponsor

Eisai Inc. — full company profile →

Who can join

18 and older, any sex, with Carcinoma, Hepatocellular. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to further characterise the hepatotoxicity in participants with advanced or unresectable hepatocellular carcinoma (HCC) treated with lenvatinib, and to further characterise the overall safety profile (serious adverse events \[SAEs\], grade 3 to 5 adverse events \[AEs\], dose modifications and discontinuations due to AEs) in participants with advanced or unresectable HCC treated with lenvatinib.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Insights in Molecular Therapies for Hepatocellular Carcinoma.
Heumann P, Albert A, Gülow K, Tümen D, et al · · 2024 · cited 5× · PMID 38791911 · DOI 10.3390/cancers16101831
An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis
Peck-Radosavljevic M, Abdelgafur A, Granito A, Gasbarrini A, et al · · 2026

Verify or expand the search:

Other trials of Lenvatinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting
NCT07493668 — Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy · Phase 2 · not yet recruiting

Other recruiting trials for Carcinoma, Hepatocellular

Currently open trials in the same condition.

NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
NCT06742892 — A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to · Phase 2 · recruiting
NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers · Phase 2 · recruiting
NCT06349980 — A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or W · Phase 2 · recruiting

Other Eisai Inc. trials

Trials by the same sponsor.

NCT07493265 — A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy · Phase 2 · not yet recruiting
NCT07308236 — A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants · Phase 1 · recruiting
NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
NCT06744673 — A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control P · active not recruiting
NCT06602258 — A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04763408 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Inc.
Last refreshed: 18 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04763408.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing